Four New ADA Studies Reveal Clinical Wins in Weight, Blood Sugar, and Healthcare Utilization

DarioHealth Corp. (DRIO:NASDAQ) announced the presentation of four studies at the American Diabetes Association (ADA) Scientific Sessions, highlighting clinical and economic outcomes associated with sustained engagement on its digital health platform among high-risk cardiometabolic populations.

According to the company, the studies examined outcomes across members with diabetes, hypertension, and obesity, including inpatient utilization, weight management, and glycemic control. Dario stated that participants experienced 0.23 fewer hospitalizations per patient per year compared with a control group. The company noted that a prior Dario study associated similar improvements with estimated payer savings of approximately US$5,077 per participant per year.

The company also reported that its digital health intervention alone produced 6.4% weight loss at 12 months, while participants using the platform in combination with GLP-1 therapy achieved 14.3% weight loss at 12 months. Dario further reported that 44.8% of high-risk diabetes users achieved at least a 1% eA1c reduction after 12 months, and that consistent engagement was associated with both weight loss and glycemic improvement.

The four studies contribute to a body of 27 studies presented by Dario at ADA over the past eight years, according to the company. Dario said the findings support the use of a single cardiometabolic digital platform across multiple chronic conditions and reinforce its strategy of expanding closer to care through claims-based and outcomes-driven payment models.

"These studies reinforce the central promise of Dario's platform: sustained engagement can drive measurable clinical improvement in high-risk cardiometabolic populations," Lara Dodo, Chief Operations Officer of Dario, said in a company news release. "For enterprise buyers, the value is not just better individual outcomes. It's the ability to address diabetes, hypertension, obesity, and weight management through one integrated platform rather than a fragmented set of point solutions."

Yifat Hershcovitz, PhD, Vice President of Clinical & Scientific Affairs at Dario, said in the release that the studies showed consistent results across utilization, weight, and glycemic control measures. "Whether the focus is utilization, weight, or glycemic control, the data show that members who stay meaningfully engaged can achieve important improvements," Hershcovitz said.

Dario stated that its platform combines AI-driven engagement tools, connected devices, and personalized coaching to support behavior change across diabetes, hypertension, and weight management programs.

Digital Health Adoption Accelerates Across Chronic Care

According to a May 21 report from MarketsandMarkets, the global digital health market was projected to grow from US$199.1 billion in 2025 to US$573.5 billion by 2030, representing a compound annual growth rate of 23.6%. The firm wrote that "rising adoption of telehealth, wearable devices, mobile health applications, and AI-powered healthcare platforms" was transforming interactions between patients and healthcare providers across the healthcare ecosystem.

MarketsandMarkets reported that chronic diseases remained a major driver of digital health adoption. The firm stated that "the growing elderly population and rising prevalence of chronic diseases such as diabetes, cardiovascular disorders, and neurological conditions" were increasing demand for digital healthcare solutions. According to the report, remote monitoring systems, AI-enabled diagnostics, and connected care platforms were helping providers deliver continuous and personalized care while reducing hospital visits and operational burdens.

Artificial intelligence also continued to play an expanding role across the sector. MarketsandMarkets wrote that "artificial intelligence is becoming central to the development of intelligent healthcare ecosystems," adding that AI-powered analytics, predictive diagnostics, and automated clinical workflows were helping providers improve decision-making and patient outcomes. The report stated that integration of AI with wearable sensors, cloud platforms, and connected devices was supporting personalized treatment strategies and real-time patient monitoring.

Dario is centered on three priorities: the continued expansion of Dario's channel ecosystem, the scale the company was operationalizing from accounts signed in 2025, and a strategic step to move the platform closer to care.

The report further noted that diabetes represented the largest disease segment within the digital health market during 2024, driven by demand for continuous monitoring and long-term disease management.

MarketsandMarkets stated that connected glucose meters, continuous glucose monitoring systems, and AI-powered diabetes management applications were improving patient engagement and treatment personalization while supporting integration into routine clinical workflows.

Additional commentary came from SNS Insider in a May 29 report examining the digital therapeutics market. The firm reported that the global digital therapeutics market was valued at US$9.98 billion in 2025 and was projected to reach US$100.0 billion by 2035. According to SNS Insider, "market growth is fueled by rising adoption of prescription digital therapeutics, increasing acceptance and use of digital therapeutics in chronic disease management, and improving integration between software-based therapeutic interventions and the pharmacological treatment pathway, including those incorporating GLP-1 therapies."

The report stated that the commercialization of prescription digital therapeutics continued to expand across diabetes, mental health, obesity management, substance use disorders, insomnia, and cardiovascular care. SNS Insider wrote that "more than 40 prescription digital therapeutics were granted FDA authorization or were undergoing active review in 2025, compared with fewer than five in 2020," reflecting increasing regulatory activity and product development within the sector.

SNS Insider also identified growing convergence between pharmaceutical treatments and digital platforms. The report stated, "We are seeing more and more companies creating integrated drug-digital treatment models that combine medication adherence support with AI-coaching, behavioral modification, and remote monitoring capabilities for obesity and cardiometabolic disease management."

Within digital therapeutics, diabetes remained the largest application segment, accounting for approximately 29.3% of the market in 2025, according to SNS Insider. The firm stated that the segment's position reflected the scale of the global diabetic population and the need for sustained lifestyle management, while real-time glucose monitoring integration, AI-powered coaching, and lifestyle intervention programs continued to expand clinical evidence supporting adoption.

The report also found that business-to-business channels represented approximately 66% of the digital therapeutics market in 2025, with employer health benefits, payer formularies, and hospital procurement serving as the primary commercialization pathways. Providers were identified as the fastest-growing end-user segment as digital therapeutic prescribing became more integrated into chronic disease management workflows.

SNS Insider also reported that diabetes remained the largest application segment within the digital therapeutics market, accounting for approximately 29.3% of the market in 2025. The report stated that growth in the segment was supported by real-time glucose monitoring integration, AI-powered insulin optimization coaching, and lifestyle intervention programs. The firm also noted increasing integration between digital therapeutics and GLP-1 therapies, with companies developing platforms that combine medication adherence support, AI coaching, behavioral modification, and remote monitoring for obesity and cardiometabolic disease management.

According to an April 27  report from ThinkEquity analyst Ashok Kumar, PhD, CFA, the firm maintained its "BUY" rating and US$25.00 price target on DarioHealth Corp. Kumar wrote that "the reported evidence still supports a constructive, but risk-adjusted, view." He added that "2025 results and subsequent disclosures show lower operating expense, higher gross margin, and a larger signed and late-stage commercial base than the equity appears to credit."

The ThinkEquity report stated that Dario's 2025 Form 10-K reported revenue of US$22.4 million compared to US$27.0 million in 2024, while management attributed the decline to "a scope change and non-renewal from one legacy Twill client." Kumar also wrote that Dario signed 85 agreements in 2025, identified US$12.9 million of contracted and late-stage ARR expected to contribute in 2026 and 2027, and ended the year with a US$122 million pipeline.

Kumar stated that "the platform case is strongest when limited to reported metrics" and noted that the 2025 Form 10-K showed "57% GAAP gross margin, up from 49% in 2024." The report also referenced disclosures from the March 19 earnings materials and April 2026 investor presentation stating that "the core B2B2C recurring business has sustained roughly 80% non-GAAP gross margin."

In a May 12 company update, CG Capital maintained its "Outperform" rating and US$28.00 price target on DarioHealth Corp.

In the April 27 report, Kumar wrote that "the long case rests on a structural shift away from narrower point-solution selling and toward an employer, health-plan, and channel model built around multi-condition deployments." He added that management disclosed that "the majority of new 2025 contracts were for multi-condition platforms and that more than 70% of pipeline opportunities were multi-condition."

The ThinkEquity report also discussed Dario's commercial pipeline and channel activity. Kumar wrote that "Dario's commercial pipeline reached US$122 million as of December 31, 2025, across 230 opportunities, with more than 70% of pipeline opportunities described as multi-condition." The report further stated that management discussed "ramp timing for relationships involving Florida Blue, Amwell, HCSC, and Solera."

Regarding financial position, Kumar stated that "the balance sheet remains the core discount." The report noted that the company reported US$21.8 million of cash and cash equivalents, US$2.2 million of short-term bank deposits, and US$30.7 million of long-term loan obligations at December 31, 2025. Kumar added that "execution risk remains the dominant issue" and stated that "partner access and covered lives must still translate into enrolled members, renewal dollars, and recognized revenue."

The ThinkEquity report concluded, "We maintain BUY and US$25.00 because we think the core factual setup is better than it was a year ago: reported operating expense is lower, gross margin is higher, the evidence package is broader, and the company has disclosed enough signed and late-stage commercial activity to support a reasonable growth bridge if even part of it converts on schedule."

In a May 12 company update, CG Capital maintained its "Outperform" rating and US$28.00 price target on DarioHealth Corp. The report stated that DarioHealth reports first quarter 2026 results on May 13, 2026, and framed the quarter as "a quarterly checkpoint on three operating signals coming out of the FY2025 plan: sequential revenue progression off the US$5.2M Q4 2025 base, OpEx discipline against management's guided ~30% non-GAAP operating loss reduction for 2026, and the early indicators of pipeline conversion as the 85 enterprise client wins from 2025 begin implementation."

CG Capital wrote that "Q4 2025 revenue of US$5.2M was the first sequential improvement after the Twill-era client non-renewal headwind" and stated that management had confirmed on the March 19 year-end call that "sequential growth is continuing into Q1 2026."

The May 12 report stated that DarioHealth had "consolidated four formerly separate digital health businesses (diabetes, hypertension, MSK, behavioral health) onto a single technology and commercial chassis under the DarioIQ AI architecture." CG Capital added that "the platform now addresses 6+ chronic conditions across a single member experience with 100+ peer-reviewed studies."

CG Capital also wrote that "against a 40-client target, DarioHealth signed 85 enterprise agreements in 2025 — more than doubling the objective." The report referenced channel and health-plan relationships, including Aetna/CVS, UnitedHealthcare, and Florida Blue.

The report further stated that "cash flow breakeven targeted for mid-2027" had been extended from prior guidance and that "non-GAAP OpEx targeting ~$31–33M by Q4 2026." CG Capital added that "the commercial pipeline expanded to US$122M (200+ B2B2C opportunities), and 85 client agreements were signed in 2025 versus a 40-client target."

CG Capital stated that its US$28.00 price target was based on a "probability-weighted blend of three scenarios." The report said, "We maintain our Outperform rating and US$28.00 price target," while noting that "our investment thesis rests on three interlocking pillars: commercial inflection, strategic optionality, and margin transformation."

In a May 13 update, CG Capital maintained its "Outperform" rating and US$28.00 price target on DarioHealth Corp., citing first-quarter results that aligned with the firm's expectations and continued commercial expansion.

CG Capital reported that Dario generated first-quarter 2026 revenue of US$5.58 million, marking a second consecutive quarter of sequential growth, while operating expenses declined 21% year over year to US$10.5 million. The firm also noted a 10% year-over-year improvement in net cash used in operations.

The report highlighted the addition of 10 new accounts during the quarter and an expansion of the company's commercial pipeline to US$127 million across 241 opportunities, compared with US$122 million across 230 opportunities at year-end 2025. CG Capital also pointed to contracting-stage progress with what it described as the largest channel partnership in the company's history, which would increase total distribution reach to more than 175 million covered lives.

According to the report, management disclosed approximately US$13 million of contracted and late-stage business moving through implementation, while also advancing care-delivery initiatives through the GreenKey4Life Clinical Sleep Service Pathway and multiple health-system proposals. CG Capital further cited early DarioIQ results showing up to a 40% improvement in member retention and up to a 57% increase in active sessions compared with a control group.

Management Outlines Channel Growth and Strategy to Move Closer to Care

On DarioHealth's first-quarter 2026 earnings call on May 13, Chief Executive Officer Erez Raphael said the company had started the year with continued momentum, citing a second consecutive quarter of sequential revenue growth alongside ongoing reductions in operating expenses. Raphael said his remarks centered on three priorities: the continued expansion of Dario's channel ecosystem, the scale the company was operationalizing from accounts signed in 2025, and a strategic step to move the platform closer to care that he said opens new revenue streams. He framed the strategy around two compounding layers described in the prior quarter — channel partnerships that provide access to millions of covered lives through a single commercial relationship, and a multi-condition platform designed to capture a greater share of each account's population. Raphael said that the thesis was "now playing out and is being accelerated."

On channel expansion, Raphael said Dario had entered the contracting stage with what he described as the largest channel partner in the company's history. He said the relationship originated from a Day 1 anchor account that is one of the largest hospital networks in the northeastern United States, and that it was expected to provide access to approximately 65 million additional covered lives and roughly 3,500 employer relationships. Combined with existing relationships, including Solera and Amwell, Raphael said the agreement would bring Dario's total distribution reach to more than 175 million covered lives. He added that a strong sales cycle at the end of 2025 closed with nearly US$13 million in contracted and late-stage business that remained on track to contribute to revenue later in 2026 and in 2027, and said the channel model was producing contract flow outside the traditional benefits cycle.

Raphael devoted the remainder of his remarks to what he called an important strategic step: evolving the platform beyond engagement and support and toward the actual delivery of care. He said Dario had built a scalable recurring, per-engaged-member revenue model with measurable outcomes, and that the company would now expand on that foundation in a way that positions it to participate more directly in medical spending tied to outcomes.

Raphael said Dario was "uniquely positioned to lead this shift," pointing to a body of more than 100 peer-reviewed clinical studies, which he said exceeds any other company in its category, as the level of validation that payers and providers require, and as what makes outcomes-based and claims-based revenue models possible. He said the company intended to advance the strategy through partnerships rather than by building every clinical capability internally, describing it as a more efficient path to broaden its value proposition and strengthen its relevance with health plans and employers.

Raphael identified clinical pathways, clinical gap closure, and provider-enabled capabilities — including Dario's expanded work with GreenKey Health — as the mechanisms for that shift, which he said would move the company from a digital engagement platform that drives behavior change toward a broader healthcare platform able to support care delivery, document outcomes, and share in the healthcare dollars tied to those outcomes.

Commercial Expansion and Pipeline Activity

Information presented in Dario's May 2026 corporate presentation outlined several commercial and operational developments. The company reported signing 85 new accounts during 2025 and an additional 10 new accounts during the first quarter of 2026, bringing its total client base to more than 160 customers. The presentation stated that Dario had US$12.9 million in contracted and late-stage annual recurring revenue expected to contribute revenue in 2026 and 2027, along with a commercial opportunity pipeline valued at US$127 million across 241 primarily B2B2C contracts.

The company reported that approximately 70% of new contracts and pipeline opportunities involve multi-condition offerings and that it maintains a 90% client retention rate. Dario also stated that 95 new contracts had been secured through the end of the first quarter of 2026, with average contract sizes ranging from two to 10 times historical levels.

For employer customers, Dario's presentation identified 44 new opportunities representing US$35 million in pipeline value for 2026 and 58 opportunities representing US$19 million in pipeline value for 2027. Combined, the employer pipeline consists of 102 opportunities valued at US$54 million.

The company's health plan pipeline included 70 opportunities representing US$33 million in value for 2026 and 11 opportunities representing US$27 million in value for 2027, for a combined total of 81 opportunities representing US$60 million in pipeline value. 

Dario's first-quarter 2026 financial snapshot showed revenue of US$5.6 million, which the company described as its second consecutive quarter of sequential growth, and approximately 80% non-GAAP gross margins within its B2B2C business. The company also reported US$22.4 million in revenue for full-year 2025, a 21% year-over-year reduction in GAAP operating expenses during the first quarter of 2026, and a 22% improvement in GAAP operating loss compared with the same period in 2025.

Ownership & Share Information¹

DarioHealth Corp. has a market cap of US$54.17 million, with 7.30 million shares outstanding.

The company's 52-week range is US$5.94-US$17.74.

Institutions own 39.4% of shares, while Strategic Investors own 7.5%.

Management & Insiders own 4.5% of shares, and the remaining 48.6% of shares are held by Retail.